Analysis Group to Present Research at ISPE 2026
Event: 42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting Dates: 29 August–2 September 2026 Host: International Society for Pharmacoepidemiology (ISPE) Location: Milan, Italy
Analysis Group, a global leader in drug safety epidemiology and regulatory RWE, will co-moderate one podium presentation session and present five research posters at the 42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting.
On Monday, August 31, from 3:30 to 5:00 p.m. CEST, in the Gold Room, Vice President Marianne Cunnington will co-moderate podium session 2C, “How Do Exposed Pregnancies End?”
On Tuesday, September 1, from 11:30 a.m. to 1:00 p.m. CEST, during poster session B in the Exhibition South Hall, researchers from Analysis Group – including Managing Principals Maral DerSarkissian, Mei Sheng Duh, and Mihran Yenikomshian, and Vice Presidents Marianne Cunnington, Lynn Huynh, and Enrico Zanardo – will present the following posters:
- B-011: Clinical Characteristics and Treatment Patterns in Cisplatin-Eligible versus Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients with Intent for Resection: A Multi-Country Retrospective Chart Review in Europe
- B-054: Comparison of Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study
- B-063: Real World Continuity of Care for Medicare Patients with Plaque Psoriasis Treated with Tildrakizumab and Other Treatment Classes
- B-249: More than Just Fit-for-Use Data: a Structured Framework to Support Real World Study Decision Making
On Wednesday, September 2, from 12:15 to 1:15 p.m. CEST, in the Exhibit Hall, Managing Principal Maral DerSarkissian will present a rare disease spotlight poster:
- SLC-033: Clinical Characteristics Associated with Pulmonary Hypertension among Patients with Interstitial Lung Disease: Interim Results from the PHINDER Study
Further details on the podium presentation session and posters are available in our 2026 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.
Associated People
Marianne Cunnington
Managing PrincipalDr. Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for new product submissions with regulators across multiple geographies (US, UK, Europe, Japan, South Korea); post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington spent more than 20 years as a pharmaceutical industry epidemiologist focusing on the generation of real-world evidence (RWE) to support the development and life cycle management of vaccines and pharmacological therapies. Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical RWE projects, provided epidemiological expertise for the company’s Global Safety Board, and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.